Aquinox Pharmaceuticals (AQXP) Announces Expansion Of Ongoing Phase 2 Trials Of AQX-1125, Including Acceptance Of U.S. IND
6/2/2014 9:22:38 AM
VANCOUVER, British Columbia, June 2, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today announced expansion of its ongoing Phase 2 clinical trials with its lead product candidate, AQX-1125.
Help employers find you! Check out all the jobs and post your resume.
comments powered by